INT255251

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.32
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 5.69
Pain Relevance 1.44

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Smad2) intracellular (Smad2) protein complex (Smad2)
transcription factor binding (Smad2) cytoplasm (Smad2)
Anatomy Link Frequency
chondrocyte 2
Smad2 (Mus musculus)
Pain Link Frequency Relevance Heat
Osteoarthritis 364 99.22 Very High Very High Very High
fibrosis 57 92.44 High High
antagonist 4 80.88 Quite High
Inflammation 119 79.84 Quite High
agonist 25 78.76 Quite High
cytokine 38 58.48 Quite High
imagery 5 15.40 Low Low
anesthesia 13 5.00 Very Low Very Low Very Low
metalloproteinase 12 5.00 Very Low Very Low Very Low
Pain 6 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Repression 4 100.00 Very High Very High Very High
Cleidocranial Dysplasia 3 99.44 Very High Very High Very High
Osteoarthritis 384 99.22 Very High Very High Very High
Carcinoma 5 98.88 Very High Very High Very High
Colitis 5 97.36 Very High Very High Very High
Disease 58 95.88 Very High Very High Very High
Blister 93 93.68 High High
Fibrosis 71 92.44 High High
Alzheimer's Dementia 4 91.52 High High
Ureteral Obstruction 16 83.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Specifically, ALK-4/5/7 inhibition led to increases in pSMAD1 levels and BMP-2 treatment led to a reduction in pSMAD2 levels (Figure 1).
Negative_regulation (reduction) of pSMAD2
1) Confidence 0.32 Published 2010 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2896919 Disease Relevance 0 Pain Relevance 0
Some chondrocytes will have progressed in their differentiation to an OA chondrocyte phenotype, triggered by a loss of the Smad2/3 block.
Negative_regulation (loss) of Smad2 in chondrocyte associated with osteoarthritis
2) Confidence 0.30 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875624 Disease Relevance 1.10 Pain Relevance 0.38
The latter observation shows not only that activation of the Smad1/5/8 route leads to terminal differentiation but also that loss of Smad2/3 can lead to induction of chondrocyte terminal differentiation.
Negative_regulation (loss) of Smad2 in chondrocyte
3) Confidence 0.30 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875624 Disease Relevance 0.22 Pain Relevance 0
TSA at a concentration of 500 nM substantially reduced the Smad2 phosphorylation level at 2 h.
Negative_regulation (level) of Smad2
4) Confidence 0.28 Published 2010 Journal Molecular Vision Section Body Doc Link PMC3013068 Disease Relevance 0 Pain Relevance 0.03
PAI-1 and p-Smad2 determined from Western blotting, among treated groups, was decreased compared to CONT group.
Negative_regulation (decreased) of Smad2
5) Confidence 0.27 Published 2010 Journal Journal of Korean Medical Science Section Abstract Doc Link PMC2799997 Disease Relevance 0.64 Pain Relevance 0.39
Western blot analysis of samples treated with 200 nM TSA did not completely block phosphorylation of Smad2; instead, it faintly reduced the pSmad2 levels at 2 h post-TGF?
Negative_regulation (reduced) of pSmad2
6) Confidence 0.25 Published 2010 Journal Molecular Vision Section Body Doc Link PMC3013068 Disease Relevance 0.05 Pain Relevance 0
Both BMP-2 and SB431542 were found to stimulate pSMAD1 and we also observed a non-canonical repression of pSMAD2.
Negative_regulation (repression) of pSMAD2 associated with repression
7) Confidence 0.23 Published 2010 Journal BMC Musculoskelet Disord Section Abstract Doc Link PMC2896919 Disease Relevance 0.17 Pain Relevance 0
Loss of Smad2/3 signaling is at the root of the OA process in our view.
Negative_regulation (Loss) of Smad2 associated with osteoarthritis
8) Confidence 0.22 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875624 Disease Relevance 1.00 Pain Relevance 0.37
Overexpression of dominant negative Smad3 causes neurodegeneration in cell cultures, indicating that loss of Smad2/3 signaling is involved.
Negative_regulation (loss) of Smad2
9) Confidence 0.22 Published 2010 Journal Arthritis Res Ther Section Body Doc Link PMC2875624 Disease Relevance 1.05 Pain Relevance 0.17
In experiments described herein, the ALK-5 inhibitor SB-505124 induced a marked reduction in levels of phosphorylated Smad2 (pSmad2) and downstream proteins of TGF-?
Negative_regulation (reduction) of Smad2
10) Confidence 0.19 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2956700 Disease Relevance 0.15 Pain Relevance 0
In experiments described herein, the ALK-5 inhibitor SB-505124 induced a marked reduction in levels of phosphorylated Smad2 (pSmad2) and downstream proteins of TGF-?
Negative_regulation (reduction) of pSmad2
11) Confidence 0.17 Published 2010 Journal Molecular Vision Section Body Doc Link PMC2956700 Disease Relevance 0.16 Pain Relevance 0
Suppression of pSmad2, CTGF, and ?
Negative_regulation (Suppression) of pSmad2
12) Confidence 0.17 Published 2010 Journal Molecular Vision Section Abstract Doc Link PMC2956700 Disease Relevance 0.71 Pain Relevance 0
Interestingly, mice deficient in Smad 2 develop more dysplasia and carcinomas after induction of chronic colitis.(32)
Negative_regulation (deficient) of Smad 2 associated with colitis, cleidocranial dysplasia and carcinoma
13) Confidence 0.09 Published 2008 Journal Biomarker Insights Section Body Doc Link PMC2600574 Disease Relevance 0.44 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox